Bli medlem
Bli medlem

Du är här


Saniona AB: Report from extraordinary general meeting of Saniona AB (publ)

October 13, 2016

Today, October 13, 2016, was held an extraordinary general meeting in Saniona
AB (publ) ("Saniona"). The following is a summary of the decisions taken. All
resolutions were passed with the requisite majority.

Decision to distribute all shares held by Saniona in the partly owned
subsidiary Initiator Pharma A/S

The general meeting decided that all the company's 20,841,467 shares in the
partly owned subsidiary Initiator Pharma A/S ("Initiator") shall be
distributed to Saniona's shareholders and that one (1) share in Saniona shall
confer the right to one (1) share in Initiator. The proposed dividend of SEK
402,751 is equal to the booked value of the Initiator shares as of September
26, 2016. This corresponds to a dividend of approximately SEK 0.0193 per
outstanding share of Saniona. The record date for the dividend payment is
October 21, 2016.

Determination of the number of board members and deputy board members

Due to the step down of Anker Lundemose from the board of directors, the
general meeting decided that during the period until the end of the next
annual general meeting the board of directors shall be composed of four board
members without deputies.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957,

This information is information that Saniona (publ) is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out above, at 10:45
CET on October 13, 2016.

About Saniona

Saniona is a research and development company focused on drugs for diseases of
the central nervous system, autoimmune diseases, metabolic diseases and
treatment of pain. The company has a significant portfolio of potential drug
candidates at pre-clinical and clinical stage. The research is focused on ion
channels, which makes up a unique protein class that enables and controls the
passage of charged ions across cell membranes. Saniona has ongoing
collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith
Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based
spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc.
Saniona is based in Copenhagen, Denmark, where it has a research center of
high international standard. Saniona is listed at Nasdaq First North Premier
and has about 4,400 shareholders. Pareto Securities is Certified Advisor for
Saniona. The company's share is traded under the ticker SANION. Read more at

20161013 - PR - Report from EGM 2016 - UK


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Saniona AB via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.